517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trialPaul DiSilvestro, K.N. Moore, B-G. Kim et al.|Annals of Oncology|2022Cited by 6
Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trialMichael Friedländer, Paul DiSilvestro, K.N. Moore et al.|Annals of Oncology|2018Cited by 2